M. M. Uttenreuther-Fischer

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

Alice L. Yu, M. M. Uttenreuther-Fischer, Chiun‐Sheng Huang et al. · Journal of Clinical Oncology · 1998 · 253 citations

Pharmacy, Oncology, Pharmacokinetics +17

Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients

M. M. Uttenreuther-Fischer, Chuin-Sheng Huang, Alice L. Yu · Cancer Immunology Immunotherapy · 1995 · 63 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +8

Paediatric thrombo-embolism: the influence of non-genetic factors and the role of activated protein C resistance and protein C deficiency

M. M. Uttenreuther-Fischer, Barbara Vetter, C Hellmann et al. · European Journal of Pediatrics · 1997 · 55 citations

Medicine, Hematology, Pediatrics +16

Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients

M. M. Uttenreuther-Fischer, Chuin-Sheng Huang, Ralph A. Reisfeld et al. · Cancer Immunology Immunotherapy · 1995 · 52 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +8

A Neoadjuvant, Randomized, Open-Label Phase II Trial of Afatinib Versus Trastuzumab Versus Lapatinib in Patients With Locally Advanced HER2-Positive Breast Cancer

Mothaffar F. Rimawi, Sabina B. Aleixo, Ashley Alarcon Rozas et al. · Clinical Breast Cancer · 2014 · 41 citations

Medicine, Oncology, Pharmacology +16